[go: up one dir, main page]

UY35409A - 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina - Google Patents

2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina

Info

Publication number
UY35409A
UY35409A UY0001035409A UY35409A UY35409A UY 35409 A UY35409 A UY 35409A UY 0001035409 A UY0001035409 A UY 0001035409A UY 35409 A UY35409 A UY 35409A UY 35409 A UY35409 A UY 35409A
Authority
UY
Uruguay
Prior art keywords
orexine
modulators
receiver
compounds
substitutes
Prior art date
Application number
UY0001035409A
Other languages
English (en)
Inventor
Jeannie M Ziff
Terry P Lebold
Brock T Shireman
Christine F Gelin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY35409A publication Critical patent/UY35409A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se dirige a los compuestos de la Fórmula I, en donde los sustituyentes son tales como se establecen en las reivindicaciones. Se describen, además, métodos para preparar los compuestos de la Fórmula I. la invención se relaciona, además, con composiciones farmacéuticas que comprenden los compuestos de la Fórmula I. los métodos para usar los compuestos de la invención están, además, dentro del alcance de la invención.
UY0001035409A 2013-03-13 2014-03-13 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina UY35409A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
UY35409A true UY35409A (es) 2014-09-30

Family

ID=50487148

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035409A UY35409A (es) 2013-03-13 2014-03-13 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina

Country Status (39)

Country Link
US (5) US9611277B2 (es)
EP (4) EP2970314B1 (es)
JP (1) JP6275815B2 (es)
KR (1) KR102209424B1 (es)
CN (3) CN108864093A (es)
AR (1) AR095423A1 (es)
AU (2) AU2014248680B2 (es)
BR (1) BR112015022294B1 (es)
CA (1) CA2904618C (es)
CL (1) CL2015002609A1 (es)
CR (2) CR20210523A (es)
CY (3) CY1120024T1 (es)
DK (2) DK3363438T3 (es)
EA (1) EA029276B1 (es)
ES (3) ES2760564T3 (es)
HK (1) HK1219725A1 (es)
HR (3) HRP20230633T1 (es)
HU (3) HUE063608T2 (es)
IL (2) IL240466B (es)
JO (1) JOP20140092B1 (es)
LT (2) LT2970314T (es)
ME (2) ME03572B (es)
MX (2) MX368466B (es)
MY (1) MY183725A (es)
NI (1) NI201500130A (es)
NO (1) NO3107630T3 (es)
PE (1) PE20151599A1 (es)
PH (1) PH12015501929A1 (es)
PL (3) PL3622956T3 (es)
PT (2) PT2970314T (es)
RS (3) RS64551B9 (es)
SG (1) SG11201507415QA (es)
SI (2) SI2970314T1 (es)
SM (3) SMT201800056T1 (es)
TW (1) TWI621618B (es)
UA (1) UA118669C2 (es)
UY (1) UY35409A (es)
WO (1) WO2014165070A1 (es)
ZA (1) ZA201507562B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120105449A (ko) 2009-10-23 2012-09-25 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
CN106414439B (zh) 2014-03-06 2017-12-08 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
EP3191468B1 (en) * 2014-09-11 2018-12-12 Janssen Pharmaceutica NV Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016100157A2 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
US10668066B2 (en) 2015-08-14 2020-06-02 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
PH12018501903B1 (en) 2016-03-10 2023-03-17 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2018098361A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
US11660293B2 (en) 2017-09-01 2023-05-30 Chronos Therapeutics Limited Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
JP2022513846A (ja) * 2018-12-14 2022-02-09 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用
CN113302190B (zh) 2019-01-15 2024-10-18 吉利德科学公司 Fxr(nr1h4)调节化合物
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
WO2004069816A1 (en) 2003-02-07 2004-08-19 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
CA2516329A1 (en) 2003-02-21 2004-09-02 Pharmacia & Upjohn Company Llc Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
JP2009519986A (ja) 2005-12-20 2009-05-21 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体のモジュレーターとしてのニコチン酸誘導体
WO2008031550A2 (en) 2006-09-11 2008-03-20 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
ATE496043T1 (de) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
US8030495B2 (en) * 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
ATE524460T1 (de) 2007-07-17 2011-09-15 Bristol Myers Squibb Co Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
EP2234999A1 (en) 2007-12-21 2010-10-06 F. Hoffmann-La Roche AG Heteroaryl derivatives as orexin receptor antagonists
RU2010138640A (ru) * 2008-02-21 2012-03-27 Актелион Фармасьютиклз Лтд (Ch) Производные 2-аза-бицикло [2.2.1] гептана
CA2722347A1 (en) 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
WO2010048016A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
WO2010048012A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
MX2011005800A (es) 2008-12-02 2011-06-20 Glaxo Group Ltd Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos.
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
KR20120105449A (ko) 2009-10-23 2012-09-25 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
CA2781390A1 (en) 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
US8697691B2 (en) 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159657A1 (en) 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014066196A1 (en) 2012-10-23 2014-05-01 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
EP2920171B1 (en) 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
US9452986B2 (en) 2014-02-06 2016-09-27 Abbvie Inc. 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
EP3191468B1 (en) 2014-09-11 2018-12-12 Janssen Pharmaceutica NV Substituted 2-azabicycles and their use as orexin receptor modulators

Also Published As

Publication number Publication date
US9845333B2 (en) 2017-12-19
CY1126106T1 (el) 2023-11-15
TW201446757A (zh) 2014-12-16
US10183953B2 (en) 2019-01-22
CR20210523A (es) 2021-11-19
AU2018204835B2 (en) 2019-08-08
US20150174129A1 (en) 2015-06-25
NI201500130A (es) 2015-11-30
SG11201507415QA (en) 2015-10-29
CY1120024T1 (el) 2018-12-12
SMT201800056T1 (it) 2018-03-08
CN108864093A (zh) 2018-11-23
PE20151599A1 (es) 2015-11-12
SI3363438T1 (sl) 2019-11-29
RS59466B1 (sr) 2019-11-29
MX2015011815A (es) 2016-11-07
ZA201507562B (en) 2019-04-24
US20170015651A1 (en) 2017-01-19
US20160052939A1 (en) 2016-02-25
CA2904618A1 (en) 2014-10-09
MX361529B (es) 2018-12-07
PL3363438T3 (pl) 2020-02-28
US20170204096A1 (en) 2017-07-20
BR112015022294B1 (pt) 2022-09-13
JP2016512535A (ja) 2016-04-28
CY1122392T1 (el) 2021-01-27
NZ710872A (en) 2020-10-30
RS64551B9 (sr) 2023-12-29
EA201591703A1 (ru) 2016-02-29
EP2970314A1 (en) 2016-01-20
IL264606A (en) 2019-02-28
SMT201900655T1 (it) 2020-01-14
BR112015022294A2 (pt) 2017-07-18
EP3622956B9 (en) 2023-09-27
RS56875B1 (sr) 2018-04-30
US9447117B2 (en) 2016-09-20
HK1219725A1 (zh) 2017-04-13
PT2970314T (pt) 2018-03-05
PH12015501929B1 (en) 2016-01-04
HUE063608T2 (hu) 2024-01-28
ES2659397T3 (es) 2018-03-15
EP3622956B1 (en) 2023-06-07
IL240466B (en) 2019-03-31
NO3107630T3 (es) 2018-01-06
SI2970314T1 (en) 2018-02-28
AU2018204835A1 (en) 2018-07-19
ES2760564T3 (es) 2020-05-14
MX368466B (es) 2019-10-03
US20140275118A1 (en) 2014-09-18
CL2015002609A1 (es) 2016-03-28
ME03572B (me) 2020-07-20
EP3363438B1 (en) 2019-09-18
CA2904618C (en) 2021-12-07
CR20150433A (es) 2015-10-26
PL3622956T3 (pl) 2023-09-18
LT3363438T (lt) 2019-11-11
US9611277B2 (en) 2017-04-04
AU2014248680B2 (en) 2018-07-26
EP2970314B1 (en) 2017-12-13
EP4272824A3 (en) 2024-01-10
HUE036193T2 (hu) 2018-06-28
EP3622956C0 (en) 2023-06-07
AR095423A1 (es) 2015-10-14
HUE047592T2 (hu) 2020-05-28
HRP20230633T1 (hr) 2023-09-29
HRP20192032T1 (hr) 2020-02-07
UA118669C2 (uk) 2019-02-25
ME03011B (me) 2018-10-20
KR20150126694A (ko) 2015-11-12
KR102209424B1 (ko) 2021-01-29
DK3363438T3 (da) 2019-11-11
EP3363438A1 (en) 2018-08-22
US8969352B2 (en) 2015-03-03
RS64551B1 (sr) 2023-10-31
PL2970314T3 (pl) 2018-05-30
EA029276B1 (ru) 2018-03-30
EP4272824A2 (en) 2023-11-08
CN105308048A (zh) 2016-02-03
CN110669052B (zh) 2022-10-11
SMT202300223T1 (it) 2023-09-06
TWI621618B (zh) 2018-04-21
JP6275815B2 (ja) 2018-02-07
IL240466A0 (en) 2015-09-24
CN110669052A (zh) 2020-01-10
LT2970314T (lt) 2018-02-12
PH12015501929A1 (en) 2016-01-04
PT3363438T (pt) 2019-12-11
WO2014165070A1 (en) 2014-10-09
JOP20140092B1 (ar) 2021-08-17
MY183725A (en) 2021-03-10
HRP20180303T1 (hr) 2018-03-23
DK2970314T3 (en) 2018-02-26
ES2950032T3 (es) 2023-10-04
AU2014248680A1 (en) 2015-08-27
CN105308048B (zh) 2019-10-08
EP3622956A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
UY35409A (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
UY35408A (es) 7-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
UY35410A (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
UY35447A (es) Moduladores de p2x7
UY35469A (es) Moduladores de p2x7
DOP2016000145A (es) Reguladores de nrf2
UY35915A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017000969A1 (es) Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014)
DOP2017000298A (es) Reguladores de nrf2
NI201400080A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35467A (es) Compuestos orgánicos
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
BR112017004742A2 (pt) 2-azabiciclos substituídos e seus usos como moduladores de receptor de orexina
NI201600015A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
DOP2015000076A (es) Benzamidas
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20150511A (es) Nuevos derivados de purina
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220902